Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Surg Infect (Larchmt) ; 18(3): 345-349, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28394748

RESUMEN

BACKGROUND: The aim of the study was to describe the microbiology and susceptibility patterns in acute cholecystitis by examining bile culture results from patients who underwent percutaneous cholecystostomy and examine concordance with empiric treatment. PATIENTS AND METHODS: A total of 124 patients with acute cholecystitis underwent percutaneous cholecystostomy between 2003 and 2012 at Emek Medical Center, Israel. Data on bile and blood culture results, isolate susceptibility, and clinical outcomes were retrieved from patient files. RESULTS: Bile cultures obtained from 116 patients were positive in 70 (60.3%) patients. Blood cultures obtained from 77 patients were positive in 23 (31.1%). Escherichia coli was the most common isolate in 28.6% of bile cultures and 43.5% of blood cultures. The concordance between empiric treatment coverage and culture isolate susceptibility was 67.6%. In most discordant cases, the isolates were Enterobacter spp. (40.9%) and Enterococcus spp. (31.8%). Overall, the in-hospital mortality rate was 7%: 2% in patients with concordant treatment compared with 14% in patients with discordant treatment (p = 0.09). Empiric antibiotic regimens were adequate in only two-thirds of patients. CONCLUSIONS: There might be a trend for poorer outcome in patients treated with inadequate antibiotic agents, emphasizing the importance of tailoring antibiotic treatment.


Asunto(s)
Antibacterianos/uso terapéutico , Bacterias/efectos de los fármacos , Bilis/microbiología , Colecistitis Aguda/microbiología , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/farmacología , Bacterias/clasificación , Bacterias/aislamiento & purificación , Colecistitis Aguda/tratamiento farmacológico , Colecistitis Aguda/cirugía , Colecistostomía , Femenino , Humanos , Israel , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Resultado del Tratamiento
2.
Am J Perinatol ; 32(13): 1247-50, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26023907

RESUMEN

OBJECTIVE: The purpose of our study was to determine whether the current antibiotic regimen for preterm premature rupture of membranes (PPROM) is adequate for covering the current causative agents and sensitivities of chorioamnionitis and early-onset neonatal sepsis. STUDY DESIGN: During a 3-year period, we retrieved the results from placental and amniotic membrane cultures obtained at delivery in cases of maternal fever, chorioamnionitis, and PPROM, and from blood cultures obtained from neonates with early-onset sepsis (EOS) in three participating hospitals. Sensitivity of pathogens to antimicrobial agents was performed using routine microbiologic techniques. RESULTS: There were 1,133 positive placental or amniotic cultures, 740 (65.3%) were from gram-negative Enterobacteriaceae. There were 27 neonates diagnosed with EOS with positive blood cultures. Aerobic Enterobacteriaceae accounted for 14 cases (52%) and group B streptococcus for 7 cases (26%). Of the Escherichia coli and Klebsiella sp., only 38% were sensitive to ampicillin. CONCLUSION: Local pathogens and their antibiotic sensitivity profiles should be explored every few years and an effective antibiotic protocol chosen to cover the main pathogens causing chorioamnionitis and EOS. Consideration should be made for changing ampicillin in women with PPROM to a regimen with better coverage of gram-negative Enterobacteriaceae.


Asunto(s)
Antibacterianos/uso terapéutico , Corioamnionitis/prevención & control , Rotura Prematura de Membranas Fetales/tratamiento farmacológico , Enfermedades del Recién Nacido/prevención & control , Sepsis/prevención & control , Amnios/microbiología , Amoxicilina/uso terapéutico , Ampicilina/uso terapéutico , Corioamnionitis/microbiología , Clindamicina/uso terapéutico , Protocolos Clínicos , Farmacorresistencia Bacteriana , Infecciones por Enterobacteriaceae/microbiología , Infecciones por Enterobacteriaceae/prevención & control , Infecciones por Escherichia coli/microbiología , Infecciones por Escherichia coli/prevención & control , Femenino , Gentamicinas/uso terapéutico , Humanos , Recién Nacido , Enfermedades del Recién Nacido/microbiología , Infecciones por Klebsiella/microbiología , Infecciones por Klebsiella/prevención & control , Pruebas de Sensibilidad Microbiana , Placenta/microbiología , Embarazo , Estudios Retrospectivos , Roxitromicina/uso terapéutico , Sepsis/microbiología , Infecciones Estreptocócicas/microbiología , Infecciones Estreptocócicas/prevención & control , Streptococcus agalactiae
3.
J Cataract Refract Surg ; 35(12): 2109-14, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19969216

RESUMEN

PURPOSE: To assess the effectiveness of adding topical moxifloxacin 0.5% to topical povidone-iodine 5.0% for preoperative reduction of bacterial recovery from the conjunctiva. SETTING: Emek Medical Center, Afula, Israel. METHODS: The study population comprised adult patients scheduled for elective intraocular surgery. Two hours before surgery, patients were randomly assigned to topical therapy with moxifloxacin 0.5% drops (study group) or normal saline drops (control group). Povidone-iodine 5% solution was also instilled in the conjunctival sac in both groups for 3 minutes immediately before surgery. Conjunctival cultures were obtained before prophylactic therapy and just before surgery. The major outcome measures were the rate of bacterial colonization and bacterial type in conjunctival cultures obtained after instillation of povidone-iodine and immediately before surgery. RESULTS: Overall, 464 patients completed the study; there were 237 patients in the study group and 227 patients in the control group. Positive conjunctival cultures were obtained before prophylactic therapy in 91 patients (38%) in the study group and 94 patients (41%) in the control group and just before surgery in 10 patients (4%) and 6 patients (3%), respectively; neither difference was statistically significant. Coagulase-negative Staphylococcus was the most prevalent bacteria and was found equally in both groups. CONCLUSIONS: Treatment with povidone-iodine 5.0% alone was effective in preoperative reduction of conjunctival bacterial colonization. Adding topical moxifloxacin 0.5% to povidone-iodine 5.0% had no significant effect on further reduction in the bacterial colonization rate.


Asunto(s)
Antiinfecciosos Locales/uso terapéutico , Profilaxis Antibiótica , Compuestos Aza/uso terapéutico , Bacterias/aislamiento & purificación , Conjuntiva/microbiología , Infecciones Bacterianas del Ojo/prevención & control , Povidona Yodada/uso terapéutico , Quinolinas/uso terapéutico , Administración Tópica , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Recuento de Colonia Microbiana , Método Doble Ciego , Quimioterapia Combinada , Femenino , Fluoroquinolonas , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Procedimientos Quirúrgicos Oftalmológicos , Cuidados Preoperatorios , Estudios Prospectivos , Infección de la Herida Quirúrgica/prevención & control , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA